Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
D&D sees fibrosis improvements, MASH resolution on GLP-1 drug
D&D linked its GLP-1/glucagon drug to liver health improvements, keeping the Korean biotech in the hunt for a market already served by Novo's Wegovy.
Nick Paul Taylor
May 27, 2026 10:30am
OSE turns up the heat on ovarian cancer with phase 2 win
May 22, 2026 7:14am
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
May 22, 2026 6:12am
Lilly’s triple-G drug drives deep weight loss in phase 3 trial
May 21, 2026 10:27am
Nominations now open for Fierce Biotech's 2026 Fierce 15
May 18, 2026 9:44am
Ipsen unveils data that drove anti-wrinkle jab into phase 3
May 18, 2026 5:06am
